Cold-FX is a product derived from the roots of North American ginseng (Panax quinquefolius). It was formulated by Jacqueline Shan and originally manufactured by her company, Afexa Life Sciences (formerly called CV Technologies), which was acquired by Valeant Pharmaceuticals in 2011. There is little evidence to support that Cold-fx is effective in the common cold. All trials have been done by the manufacturer and there has been poor data reporting. According to Health Canada's Natural Health Product Directorate records, the company claims that it may "help reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system". COLD-FX is licensed by Health Canada as a Natural Health Product. The efficacy of this extract has been tested in clinical trials conducted in collaboration with researchers from Canadian universities. COLD-FX has been assessed in 6 published randomized, double-blinded and placebo controlled clinical trials and 20+ published articles. The product has not been shown to reduce the number or severity of common colds.